Shivalik Rasayan Files USFDA Drug Master File for Avapritinib API
Shivalik Rasayan Ltd 路 Others (Uncategorized) 路 03 Nov 2026, 7:25 pm
Shivalik Rasayan Files USFDA Drug Master File for Avapritinib API Shivalik Rasayan Limited has successfully filed a Drug Master File (DMF) with the USFDA for Avapritinib API, with the Complete Assessment already concluded. Avapritinib is indicated for the treatment of Gastrointestinal Stromal Tumors (GIST). The innovator product, marketed by Sanofi under the brand name Ayvakit, generated global revenues of USD 700 million during CY25. This regulatory milestone positions the company to target a commercially significant oncology market opportunity in the United States.
Original exchange filing (PDF)
More announcements from Shivalik Rasayan Ltd
- Shivalik Rasayan Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 14 Nov 2026
- We wish to inform that the Board of Directors of the Company at its meeting held on today approved the un-audited financial results (standalone & consolidated) for the quarter and half .... 路 14 Nov 2026
- Shivalik Rasayan Limited has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . 路 13 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 路 13 Nov 2026
- Shivalik Rasayan Limited has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . 路 13 Nov 2026
- Shivalik Rasayan Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Un-Audited Financial Results .... 路 13 Nov 2026
- Voting Results along with Scrutinizer''s Report for the 48th Annual General Meeting held on 28.09.2026 路 29 Sept 2026
- Disclosure pursuant to Regulation 29(1) of SEBI SAST Regulations, 2011 路 29 Sept 2026
